Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

Needham upgraded Boston Scientific Corp (NYSE:BSX) to “Buy”, saying competition from pulsed field ablation (PFA) rivals looks less intense for its key product than it was earlier feared, and citing ...

Needham upgraded Boston Scientific (BSX) to Buy from Hold with a $113 price target Needham’s latest electrophysiologist survey shows the ...

Boston Scientific announced via social media that it has closed the acquisition of Bolt Medical, which recently gained FDA ...

Boston Scientific’s $664m bet on Bolt Medical has paid off, as the company’s intravascular lithotripsy (IVL) system gains US Food and Drug Administration (FDA) clearance. Whilst neither Bolt ...

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular lithotripsy (IVL) system, positioning ...

Recent acquisitions are also seen as adding to Boston Scientific’s growth story. Bolt Medical’s new device for treating artery disease recently gained U.S. approval, while SoniVie is ...

Elixir trails J&J’s Shockwave but has outpaced Bolt Medical to the European market with its mechanical IVL system.